Human Papilloma Virus (HPV) is a sexually transmittable virus and is the main etiologic cause of uterine cervical cancers. Beyond that, vitamin D is a steroid structured lipid-soluble vitamin, enhancing both humoral and cellular immune responses. In our study, we aimed to investigate the relationship between vitamin D levels and high-risk HPV infections.Material and methods: A total of 143 patients who applied to the gynecology outpatient clinic between June 2020 and August 2020 were included in the study. Patients with high-risk HPV positivity constituted the study group, and HPV-negative patients constituted the control group. Serum vitamin D levels were compared between the groups.Results: The mean vitamin D level of all patients included in the study, HPV(+) and HPV(-) patients were 17.57±8.73, 17.54±9.20 and 17.63±7.83, respectively. In the study group 10.2% of the patients and in the control group 8.5% had adequate vitamin D levels. No significant differences in vitamin D levels and in terms of distribution according to categorical vitamin D level have been observed between the groups (p=0.774, p=0.989).Conclusion: Vitamin D levels were comparable between HPV positive and HPV negative groups, but study and controls both had very low sufficient vitamin D levels. In Turkey and especially in our region (Zonguldak), vitamin D deficiency is almost endemic, and this might be the main reason that both of the groups have very similar vitamin D measurements.

Objective: Preimplantation-factor (PIF) is a new peptide with many potential functions. We aimed to compare the maternal serum PIF levels among early-onset preeclamptic patients with the healthy controls at the same gestational age. Patients and Methods: Thirty-nine early-onset preeclamptic (< 34 gestational weeks) patients and 45 healthy expecting women have been added to our study. Patients with or suspicion of any chronical maternal disease, gestational diabetes, twin pregnancies, fetal or placental anomalies or any other obstetric complications have been excluded. Competitive enzyme-linked immunosorbent assay (ELISA) (Elabscience Biotechnology Co., Texas, USA) has been used to analyze the PIF levels in the collected samples. Gestational age, maternal age, gravida, parity, fetal growth, body mass index (BMI), maternal weight and height, plasma PIF levels have been collected/measured and analyzed in both groups. Results: The primary outcome of our study –the Preimplantation Factor- was significantly higher in study group than the healthy controls (100.36 ± 41.92 vs. 83.14 ± 51.27 p=0.016). Conclusions: We have found the PF levels statistically higher in the study group. PIF levels might have a role in the progression and pathogenesis of the preeclamptic patients. Further studies with larger groups have to be planned and performed to resolve the real relation between PIF and preeclampsia.

No abstract